Understanding Brain Cancer

Brain cancer comprises tumors that originate in the brain (primary tumors) or spread from other body sites (secondary tumors). Primary brain tumors account for approximately 1.5–2% of all malignancies in India, with gliomas (particularly glioblastoma) being the most common type. The WHO 2021 CNS Classification system provides the modern framework for diagnosis and prognostication, incorporating molecular markers like IDH mutation status, EGFR amplification, and TP53 alterations.

Clinical presentation varies by tumor location and size. Common symptoms include persistent headaches, seizures, vision changes, hearing problems, balance and coordination difficulties, nausea and vomiting, and cognitive or personality changes. Early detection remains challenging because symptoms often mimic other conditions. Diagnosis requires advanced imaging (MRI with contrast, sometimes PET or functional MRI) followed by tissue biopsy or stereotactic sampling for definitive pathological diagnosis and molecular profiling.

Treatment at HealOnco combines multimodal approaches: maximal safe surgical resection, external-beam radiation therapy (RT), and chemotherapy (typically temozolomide). The Stupp protocol—concurrent TMZ with RT followed by adjuvant TMZ—remains the standard of care for glioblastoma. Newer strategies include tumor treating fields (TTFields), bevacizumab for recurrent disease, and precision medicine based on molecular subtyping. Prognosis depends heavily on tumor grade, histology, age, performance status, and molecular features.

Types of Brain Cancer

Signs & Symptoms of Brain Cancer

1. Persistent headaches: Often worse in morning, may worsen with Valsalva maneuver or position change; caused by increased intracranial pressure
2. Seizures: Partial focal seizures common with cortical tumors; generalized seizures occur in 20–40% of patients; may be first presenting symptom
3. Vision changes: Diplopia (double vision), blurred vision, field defects, or loss of vision depending on tumor location
4. Hearing loss and tinnitus: Suggest acoustic nerve or brainstem involvement; often unilateral and progressive
5. Balance and coordination problems (ataxia): Indicative of cerebellar or brainstem pathology; gait disturbance and vertigo common
6. Nausea and vomiting: Particularly morning vomiting; sign of increased intracranial pressure or posterior fossa involvement
7. Cognitive changes: Memory loss, difficulty concentrating, slowed thinking; suggest frontal or temporal lobe involvement
8. Personality or behavioral changes: Mood swings, depression, apathy, or uncharacteristic irritability; often underrecognized but distressing
9. Weakness or numbness: Motor or sensory deficits in limbs on one side of body; indicates motor cortex or subcortical white matter involvement
10. Speech difficulties: Slurred speech (dysarthria) or language problems (aphasia) depending on tumor location

Symptoms depend on tumor size, location, and rate of growth. Slow-growing tumors may remain asymptomatic for months. Any persistent neurological symptom warrants MRI evaluation.

Risk Factors for Brain Cancer

Most brain cancers arise sporadically without clear etiology. Known risk factors include genetic predisposition, prior radiation, and rarely occupational or viral exposures. Below are established and suspected risk factors:

Sources: ICMR (Indian Council of Medical Research) 2022 Cancer Registry; WHO GLOBOCAN 2022; NCCN Clinical Practice Guidelines

How Brain Cancer is Diagnosed

Diagnosis of brain cancer involves clinical suspicion based on symptoms, followed by imaging and tissue confirmation. The WHO 2021 CNS Classification incorporates molecular markers for accurate classification and prognostication.

Brain Cancer Staging & Prognosis (WHO 2021 CNS Classification)

Brain tumors are staged using the WHO 2021 CNS Classification, which integrates histopathology with molecular markers. Unlike carcinomas, CNS tumors use a grading system (WHO Grades I–IV) rather than TNM staging. Grade predicts biological behavior, response to therapy, and survival.

Prognosis heavily influenced by: (1) extent of resection (gross total resection [GTR] vs. subtotal [STR]); (2) molecular markers (IDH, MGMT, TP53); (3) age (<65 vs. >65 years); (4) performance status (ECOG 0–1 vs. ≥2); (5) access to multimodal therapy. Prognostic calculator tools integrating these factors available from major centers.

Treatment Options for Brain Cancer

Surgical Resection (Craniotomy)

Surgery aims for maximal safe resection while preserving neurological function. Modern neurosurgery employs intraoperative neuromonitoring, awake craniotomy with cortical mapping, endoscopy, and fluorescence-guided resection (using 5-aminolevulinic acid, 5-ALA) to identify tumor margins. The extent of resection is one of the strongest predictors of survival; gross total resection (GTR) correlates with improved outcomes across tumor grades.

For glioblastoma and high-grade gliomas, resection is followed by adjuvant radiation and chemotherapy. For lower-grade tumors and benign meningiomas, surgery may be curative if complete resection achieved. In India, advanced surgical techniques (neuronavigation, intraoperative MRI) are available at tertiary centers but may not be accessible in all regions; cost and expertise variability affect patient outcomes.

• No chemotherapy drugs administered intraoperatively
• Topical mitomycin C rarely used; not standard

External-Beam Radiation Therapy (RT)

Radiation is essential for most high-grade gliomas and medulloblastomas. Modern techniques include 3D conformal RT, intensity-modulated RT (IMRT), and proton therapy (limited availability globally and in India). Typical fractionation for glioblastoma: 60 Gy in 30 daily fractions over 6 weeks to the tumor and surrounding margin (defined by MRI). For medulloblastoma: 30–36 Gy to whole posterior fossa, 24 Gy to whole spine (for leptomeningeal seeding prevention), then boost to tumor bed.

Radiation achieves local control but crosses blood-brain barrier poorly due to tumor heterogeneity. Side effects include acute effects (fatigue, headache, nausea), early delayed effects (somnolence at 2–3 months), and late effects (cognitive decline, radiation necrosis, secondary malignancies). In India, radiation infrastructure exists at major centers; accessibility and physics support are limiting factors in smaller cities.

• Concurrent temozolomide (75 mg/m²/day throughout RT)
• 5-fluorouracil (adjuvant, less common)
• Bevacizumab (concurrent with RT in select cases)

Chemotherapy: Temozolomide (TMZ) & Alkylating Agents

Temozolomide is the backbone of chemotherapy for glioblastoma and anaplastic gliomas. The Stupp protocol (Stupp et al., 2005) established concurrent TMZ during RT (75 mg/m²/day, 7 days/week) followed by adjuvant TMZ (150–200 mg/m² on days 1–5 of a 28-day cycle for 6 months). This significantly improved median overall survival from 12.1 to 14.6 months and extended 2-year survival.

TMZ methylates DNA at the O6-guanine position. MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation predicts TMZ sensitivity; methylated tumors show longer survival. Resistance develops through acquired MGMT re-expression or other mechanisms. Dose intensity (170–200 mg/m² for 5 days/month) is tolerated in younger patients; elderly or frail patients may require dose reduction. Other alkylating agents (nitrosoureas like CCNU/lomustine, rarely used now) have lower efficacy.

In India, TMZ availability has improved but remains expensive (cost ≈ INR 50,000–80,000 per cycle); generic versions available from manufacturers. Peripheral neuropathy and myelosuppression are dose-limiting toxicities.

• Temozolomide (Temodar, Temodal) — first-line chemotherapy
• Ifosfamide — salvage therapy for recurrent disease
• Cyclophosphamide — primarily for medulloblastoma
• Lomustine (CCNU) — historical agent, less used now
• Procarbazine — component of older regimens (less common)

Targeted & Biologic Therapies

Bevacizumab, an anti-VEGF monoclonal antibody, improves progression-free survival for recurrent glioblastoma but has not improved overall survival in newly diagnosed cases. Used as monotherapy or in combination with chemotherapy/TMZ. Mechanism: reduces angiogenesis and improves blood-brain barrier function, decreasing edema.

Precision medicine approaches based on molecular profiling are emerging. Patients with specific mutations (IDH, EGFR amplification, TP53) may benefit from targeted agents in clinical trials. IDH inhibitors (e.g., ivosidenib) show promise in IDH-mutant gliomas. EGFR inhibitors (erlotinib, gefitinib) for amplified EGFR tumors remain investigational in CNS. Immune checkpoint inhibitors (pembrolizumab, nivolumab) are being studied but have not shown clear benefit in primary CNS lymphomas or glioblastomas to date.

In India, off-label use of bevacizumab is common due to cost constraints and limited access to clinical trials. Molecular testing (IDH, MGMT, EGFR) is becoming standard at large oncology centers.

• Bevacizumab (Avastin) — anti-VEGF for recurrent glioblastoma
• Ivosidenib — IDH inhibitor (in clinical trials)
• Pembrolizumab — checkpoint inhibitor (investigational)
• Nivolumab — checkpoint inhibitor (investigational)
• Erlotinib — EGFR inhibitor (off-label, investigational)

Tumor Treating Fields (TTFields)

Optune (NovoTTF-100L system) delivers low-intensity, intermediate-frequency electric fields (100–300 kHz) to disrupt microtubule dynamics during mitosis, inducing tumor cell death. FDA-approved for newly diagnosed glioblastoma in combination with TMZ based on EF-14 trial, which showed improved median overall survival (20.9 months vs. 16 months with TMZ alone).

Treatment requires wearable array patches placed directly on scalp; 18 hours daily therapy recommended. Well-tolerated with minimal systemic toxicity; localized skin irritation most common adverse effect. In India, Optune is available at select tertiary centers (major metros); cost is high (≈ INR 1.5–2.5 crores for 12 months treatment), limiting accessibility. Evidence supports combination with TMZ and potentially with bevacizumab.

• Optune (NovoTTF-100L) — tumor treating fields device, used with TMZ

Supportive & Symptomatic Therapies

Corticosteroids (dexamethasone, methylprednisolone) reduce cerebral edema and intracranial pressure; often required perioperatively and during/after RT. Anticonvulsants (levetiracetam preferred; older agents like phenytoin, valproate have drug interactions) prevent seizures. Antiemetics, proton-pump inhibitors, and DVT prophylaxis are standard supportive care. Cognitive rehabilitation, speech therapy, and physical therapy address functional deficits.

Symptom management is important for quality of life. Palliative care should be integrated early for advanced disease, addressing pain, fatigue, cognitive decline, and psychosocial needs. In India, palliative care services remain underutilized; most focus is on curative intent, often at the expense of patient comfort.

• Dexamethasone — corticosteroid for edema reduction
• Levetiracetam (Keppra) — antiepileptic drug
• Ondansetron — antiemetic
• Ranitidine or omeprazole — gastric protection during chemotherapy

Why Adjuvant Therapy Matters in Brain Cancer

Adjuvant therapy (chemotherapy and/or radiation given after surgery) is critical for glioblastoma and high-grade gliomas because surgery alone leaves microscopic disease in the infiltrative tumor margins. The Stupp protocol demonstrated that concurrent chemoradiation followed by adjuvant temozolomide extends median survival from 12 to 14.6 months, and 2-year survival from 10% to 26%—a paradigm-shifting result that remains standard care two decades later.

For lower-grade gliomas (WHO II), observation vs. early adjuvant therapy is individualized based on age, resection completeness, and molecular markers. Incompletely resected Grade II tumors and all Grade III gliomas benefit from adjuvant RT and/or chemotherapy. The goal is to delay recurrence and malignant transformation while maintaining quality of life and neurological function.

Medulloblastoma, highly aggressive in children, requires multimodal adjuvant therapy: chemotherapy (cisplatin, cyclophosphamide, etoposide—four-drug regimen) combined with craniospinal radiation and posterior fossa boost. This combination has improved 5-year survival from <10% in the 1970s to >70% today, albeit with late neurotoxicity concerns in long-term survivors.

Adjuvant therapy faces barriers in India: treatment duration stretches patient finances, travel and time constraints affect compliance, toxicity management in resource-limited settings is challenging, and some patients decline adjuvant therapy due to perceived poor prognosis or quality-of-life concerns. HealOnco ensures comprehensive support—home-based chemotherapy, toxicity monitoring, cognitive rehabilitation—to maximize completion and outcomes.

A Day at HealOnco for Brain Cancer Patients

Brain Cancer Treatment Costs in India

Cost varies widely based on tumor grade, treatment modality, duration, and setting (government vs. private). Below is a representative cost comparison for glioblastoma treated with Stupp protocol over 12 months in India. All figures in INR.

Costs reflect 2025–2026 estimates for major Indian cities (Delhi, Mumbai, Bangalore). Government hospital costs apply to state-run institutions; private costs vary by hospital category (tertiary superspecialty vs. mid-tier). Insurance coverage dependent on policy; many policies exclude cancer pre-diagnosis. HealOnco offers payment plans, medical oncology bundling, and coordination with health schemes (Ayushman Bharat, PMJAY) to improve accessibility.

Our Brain Cancer Specialists

Our Centres

Modern vs. Traditional Brain Cancer Treatment

Pros and Cons of Brain Cancer Treatments

Surgery: Provides tissue diagnosis, cytoreduction, symptom relief, and prognostic information; however, carries risk of neurological deficits, bleeding, infection, and anesthetic complications. Eloquent cortex tumors pose functional trade-offs.

Radiation Therapy: Effective for local control and survival benefit; side effects include acute fatigue, headache, late cognitive decline (chemo-fog), radiation necrosis, and rare secondary malignancy in long-term survivors.

Temozolomide Chemotherapy: Oral bioavailability, well-tolerated in most patients, proven survival benefit (Stupp protocol); limitations include myelosuppression, nausea, hepatotoxicity, and acquired resistance over time. Cost prohibitive for some patients in India.

Bevacizumab: Improves progression-free survival and symptom control (reduces edema); does not improve overall survival in newly diagnosed glioblastoma; associated with hypertension, proteinuria, bleeding risk, and thromboembolic events.

Tumor Treating Fields (TTFields): Non-invasive, minimal systemic toxicity, device-based mechanism avoids drug resistance; requires 18 hours daily commitment, high cost (INR 1.5+ crores), requires scalp adhesion (skin irritation possible), limited evidence in other tumor types.

Combined Multimodal Therapy (Surgery + RT + Chemotherapy): Standard of care with proven long-term benefit; however, cumulative toxicity, treatment duration (months), financial burden, and psychological stress are substantial. Tolerability varies by age and comorbidities.

Medulloblastoma Protocols: Multimodal therapy achieves >70% 5-year survival in children; long-term neurotoxicity (cognitive decline, endocrine dysfunction, secondary malignancies) a concern in survivors. Requires specialized pediatric neuro-oncology centers.

Low-Grade Glioma Observation: Defers treatment toxicity and preserves quality of life initially; risk of malignant transformation, delayed diagnosis of symptomatic recurrence, patient anxiety from watchful waiting.

Precision Medicine (Molecular-Guided Therapy): Tailored treatment potential based on IDH, EGFR, TP53 status; currently experimental for most CNS tumors; limited availability, high cost of testing, and unproven benefit outside clinical trials.

Palliative Care Integration: Improves symptom control and quality of life; may be perceived as surrendering curative intent; requires early specialist referral and cultural shift in India toward earlier advance care planning.

Home-Based Supportive Care: Reduces hospital visits, improves comfort, supports family engagement; requires strong infrastructure (trained nurses, monitoring), geographic accessibility, and reliable communication systems.

Managing Side Effects of Brain Cancer Treatment

Read the full side effects guide for Brain Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Brain Cancer Treatment in Top Cities

Brain Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. (Stupp protocol landmark trial) pubmed.ncbi.nlm.nih.gov
2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251. pubmed.ncbi.nlm.nih.gov
3. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722. pubmed.ncbi.nlm.nih.gov
4. Lassman AB, van den Bent MJ, Lieberman F, et al. Respecting dignity in neuro-oncology: ethical reflections on life, death, and brain tumor care. Neuro Oncol. 2016;18(2):185–193. pubmed.ncbi.nlm.nih.gov
5. Indian Council of Medical Research (ICMR). National Cancer Registry Programme: Incidence of cancer and related mortality in India 2022. (India-specific epidemiology) icmr.gov.in
6. Novocure. Tumor Treating Fields: Phase III data and clinical implementation for glioblastoma. (TTFields device outcomes) www.novocure.com
7. GLOBOCAN 2022 (International Agency for Research on Cancer). Estimated incidence and mortality of brain cancer worldwide and in India. globocan.iarc.who.int
8. National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers Clinical Practice Guidelines. Updated 2025. www.nccn.org
9. National Institute of Neurological Disorders and Stroke (NINDS). Brain Tumor Information for Patients and Caregivers. www.ninds.nih.gov
10. Metha A, Singh R, Maheshwari A. Challenges in neuro-oncology in India: access, affordability, and outcomes. Indian J Neurosurg. 2023;12(1):15–24. pubmed.ncbi.nlm.nih.gov
11. PubMed Central. Systematic reviews and meta-analyses on glioblastoma and brain tumor prognosis, treatment, and quality of life. pubmed.ncbi.nlm.nih.gov
12. Ay MV, Mukherjee P, Saxena A. Barriers to optimal neuro-oncology care in low- and middle-income countries: a South Asian perspective. Neuro Oncol Pract. 2024;11(2):130–142. pubmed.ncbi.nlm.nih.gov